FIELD: medicine, pharmacy. SUBSTANCE: invention relates to polypeptide that is analog of epidermal growth factor fragment from 21-31 amino acids as vector used for directed delivery of antitumor preparations in tumor cells. Invention proposes also conjugate of polypeptide with doxorubicin showing selective effect with respect to cancer tumors. Pharmaceutical composition comprises effective amount of conjugate and carrier useful for intravenous administration. EFFECT: enhanced effectiveness of preparation effect. 4 cl, 3 tbl, 2 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
VECTOR POLYPEPTIDE ANALOG OF TRANSFORMING GROWTH FACTOR ALPHA (TGF) FRAGMENT, ITS ANTITUMOR CONJUGATE AND PHARMACEUTICAL COMPOSITION ON CONJUGATE BASE | 2004 |
|
RU2277930C1 |
PEPTIDE REPRESENTING ANALOG OF ALPHA-FETOPROTEIN FRAGMENT, CONJUGATE OF PEPTIDE WITH DOXORUBICIN AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF FOR TREATMENT OF ONCOLOGY DISEASE | 2006 |
|
RU2317102C1 |
PROTEIN-PEPTIDE ANTITUMOR COMPOSITION, CELL PREPARATION ACTIVATED THEREWITH AND METHOD FOR TUMOR PROPHYLAXIS OR TREATMENT | 2004 |
|
RU2283129C1 |
ANTITUMOR PEPTIDE PREPARATION BASED ON ALPHA-FETOPROTEIN FRAGMENT, ITS CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF HORMONE-DEPENDENT TUMORS | 2005 |
|
RU2285537C1 |
ANTI-TUMOUR PREPARATION | 2011 |
|
RU2451509C1 |
CONJUGATE POSSESSING SELECTIVE EFFECT WITH RESPECT TO CANCER TUMORS | 2005 |
|
RU2303997C2 |
CONJUGATE OF ANTITUMOUR DRUGS WITH RECOMBINANT ALPHA-FETOPROTEIN AND ITS FUNCTIONAL FRAGMENTS AND METHOD OF THEIR PRODUCING | 2016 |
|
RU2630974C1 |
ANTITUMOR LIPOSOMAL PREPARATION WITH DIRECTED EFEFCT | 2005 |
|
RU2292898C1 |
CONJUGATE OF BIOLOGICALLY ACTIVE SUBSTANCES WITH $$$-FETOPROTEIN SHOWING THE SELECTIVE ACTION WITH RESPECT TO CANCER TUMORS, METHOD OF THEIR PREPARING (VARIANTS) AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1996 |
|
RU2071351C1 |
HIGHLY EFFECTIVE METHOD FOR PREPARING DOSAGE FORM OF TARGETED ACTION FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2727924C1 |
Authors
Dates
2003-01-20—Published
2001-12-21—Filed